IGC starts clinical trial of drug candidate to treat agitation in dementia

India Globalization Capital (IGC) has begun a Phase II clinical trial of its drug candidate IGC-AD1 to treat agitation in dementia from Alzheimer’s Disease.

The multi-centre, randomised, double-blind, placebo-controlled trial will evaluate the efficacy and safety of the drug in these participants.